Skip to Content

Join the 'Chronic Active Hepatitis' group to help and get support from people like you.

Chronic Active Hepatitis News

Hundreds Hospitalized in San Diego as Hepatitis A Outbreak Spreads

Posted 16 days ago by Drugs.com

FRIDAY, Oct. 6, 2017 – An outbreak of hepatitis A among drug users and the homeless in San Diego continues to spread, public health experts report. To date, 481 cases have been reported, 337 people have been hospitalized and 17 have died, according to Dr. Eric McDonald. He is from the epidemiology and immunization services branch of the San Diego County Health and Human Services Agency. Cases of the viral liver disease are also now being reported in Santa Cruz and Los Angeles counties, where 70 and 12 people have been diagnosed, respectively, the Los Angeles Times reported. The first signs of the outbreak surfaced almost a year ago. "From November 2016 to February 2017, between seven and nine cases would have been expected, yet 19 cases were reported," McDonald said during a media briefing Thursday. What triggered this outbreak remains unknown and will most likely never be identified, ... Read more

Related support groups: Hepatitis A, Liver and Pancreatic Disease, Twinrix, Chronic Active Hepatitis, Infectious Hepatitis, Havrix, Hepatitis A Adult Vaccine, Vaccination and Prophlaxis, Hepatitis A Pediatric Vaccine, Vaqta Pediatric, Hepatitis A Adult Vaccine/hepatitis B Adult Vaccine, Havrix Pediatric, Hepatitis A Prophylaxis, Vaqta

Mavyret Approved for Hepatitis C

Posted 4 Aug 2017 by Drugs.com

FRIDAY, Aug. 4, 2017 --Mavyret (glecaprevir and pibrentasvir) has been approved by the U.S. Food and Drug Administration to treat adults with certain types of chronic hepatitis C virus (HCV). The combination drug is the first approved therapy for hepatitis C to require as few as eight weeks of treatment, the FDA said in a news release. Other therapies require treatment of 12 weeks or longer. "This approval provides a shorter treatment duration for many patients, and also a treatment option for certain patients . . . who were not successfully treated with other direct-acting antiviral treatments," said Dr. Edward Cox, director of the FDA's Office of Antimicrobial Products. HCV causes liver inflammation, potentially leading to reduced liver function or liver failure, the agency said. Symptoms and complications may include jaundice, a yellowing of the skin; bleeding; abdominal fluid ... Read more

Related support groups: Hepatitis C, Chronic Active Hepatitis, Mavyret, Glecaprevir/pibrentasvir

Serious Infections Tied to Suicide Risk

Posted 10 Aug 2016 by Drugs.com

WEDNESDAY, Aug. 10, 2016 – People hospitalized for serious infections may face an increased risk of dying by suicide, and researchers suspect there's a biological reason for it. In a study of over 7 million people, Danish researchers found that those who'd been hospitalized for infections were 42 percent more likely to die of suicide compared to people with no history of serious infection. People hospitalized for HIV/AIDS or the liver infection hepatitis showed the highest risk – more than twice that of people without those diseases, the study found. Although the study couldn't prove a cause-and-effect link, the study authors and at least one other brain health expert think the increased risk of suicide after infection might not simply reflect the psychological impact of serious illness. Instead, infections might directly contribute to suicide risk by causing inflammation in the ... Read more

Related support groups: Depression, Major Depressive Disorder, Hepatitis C, HIV Infection, Postpartum Depression, Hepatitis B, Dysthymia, Seasonal Affective Disorder, Hepatitis A, Neurotic Depression, Depressive Psychosis, Chronic Active Hepatitis, Infectious Hepatitis

Hepatitis C Drugs Will 'Strain Budgets' at Current Prices: Study

Posted 16 Mar 2015 by Drugs.com

MONDAY, March 16, 2015 – New hepatitis C drugs promise cure rates above 90 percent, but could prove to be budget-busters for public and private health insurers, a new analysis finds. Recently approved drugs for chronic hepatitis C have been heralded as a breakthrough that could make the liver disease "rare" in the United States. But with prices topping $1,000 per pill, government and private insurers are balking – often putting limits on which patients qualify for coverage. Now two new studies in the March 16 Annals of Internal Medicine conclude that for individual patients, treatment with the pricey pills is "cost-effective." That's a calculation that takes into account the years of better health and quality of life people will likely enjoy. The bad news? One study estimates that state governments and insurers will have to dig up an extra $65 billion over five years to get the drugs ... Read more

Related support groups: Hepatitis C, Harvoni, Sovaldi, Sofosbuvir, Chronic Active Hepatitis, Infectious Hepatitis

Ask a Question

Further Information

Related Condition Support Groups

Infectious Hepatitis

Related Drug Support Groups

Imuran, azathioprine, Azasan